Annual Reports in Medicinal Chemistry

0569226 - BC 2023 RIV US eng M - Část monografie knihy
Thames, J. E. - Eyer, Luděk - Seley-Radtke, K.
Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals.
Annual Reports in Medicinal Chemistry. Cham: Springer, 2022 - (Neidle, S.), Roč. 58 (2022), s. 55-92. ISBN 9780323988933
Grant CEP: GA MŠMT(CZ) LTAUSA18016
Institucionální podpora: RVO:60077344
Klíčová slova: Nonnucleoside inhibitor * Nucleoside analog * Small molecule-based inhibitor * Tick-borne encephalitis * Tick-borne encephalitis virus
Obor OECD: Microbiology
https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?pes=vor

Tick-borne encephalitis (TBE) is one of the most serious neurological infections in Europe and Northeastern Asia. The causative agent of TBE is the tick-borne encephalitis virus (TBEV). Although several effective vaccines are legislated to prevent TBE, there are currently no approved treatments/anti-TBEV drugs other than supportive measures. Therefore, there is an urgent medical need for the development of novel, specific, and effective antivirals to treat patients with TBEV infection. This report summarizes the available information on antiviral research on small molecule-based inhibitors of TBEV replication. The main focus is on the description of nucleoside analogs, a leading group of antiviral compounds with the highest anti-TBEV potency. Various sugar/nucleobase modifications of the nucleoside scaffold that have been made to maximize the antiviral activity and decrease the cytotoxicity of the compounds are discussed. Emphasis is also placed on elucidating the mechanism of action of the inhibitors studied and their relationship to the development of antiviral resistance. Moreover, a brief overview of nonnucleoside inhibitors, natural compounds, repurposed drugs, and synthetic broad-spectrum antivirals is also part of this chapter. The review shows that specific therapies based on small-molecule inhibitors, in combination with effective vaccination strategies, could be effective prophylactic and curative tools to control TBEV infections in humans.
Trvalý link: https://hdl.handle.net/11104/0340607